FDA Approves Oral Form of ALS Drug Edaravone FDA Approves Oral Form of ALS Drug Edaravone
The FDA has approved an orally administered version of edaravone for adults with amyotrophic lateral sclerosis.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 13, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)
FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Radicava ORS is an orally administered version of Radicava, which was originally approved in 2017 as an intravenous (IV) infusion to treat ALS, commonly referred to as Lou (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 12, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Ultra-High Dose Drug Slows Functional Decline in Early ALS Ultra-High Dose Drug Slows Functional Decline in Early ALS
An ultra-high dose of methylcobalamin slows functional decline and is safe in patients with early stage amyotrophic lateral sclerosis, results from a new phase 3 study suggest.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 12, 2022 Category: Primary Care Tags: Neurology & Neurosurgery News Source Type: news

Alzheimer's disease-related psychosis: an overview of clinical manifestations, pathogenesis, and current treatment - Benmelouka AY, Ouerdane Y, Outani O, Alnasser YT, Alghamdi BS, Perveen A, Ashraf GM, Ebada MA.
Behavioral and psychotic manifestations, including aggression, delusions, and hallucinations, are frequent comorbidities in patients with debilitating nervous illnesses such as Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis, Multiple Sclerosis, an... (Source: SafetyLit)
Source: SafetyLit - April 24, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

A Biomarker for ALS? A Biomarker for ALS?
A biomarker typically linked with Alzheimer ' s disease may also signal amyotrophic lateral sclerosis.First Look (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 21, 2022 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news

Preventing ALS: Insights From Other Neurodegenerative Diseases Preventing ALS: Insights From Other Neurodegenerative Diseases
The authors apply what we know about prodromal clinical markers in other neurodegenerative diseases to amyotrophic lateral sclerosis. Might early therapeutic intervention--or prevention--be possible?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Nanoparticle Shows Promise for ALS Nanoparticle Shows Promise for ALS
A novel treatment for amyotrophic lateral sclerosis that would represent a novel mechanism of action showed signs of efficacy when used with riluzole in a phase 2 trial.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 7, 2022 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

Ronnie Corbett: Star's secret motor neurone diagnosis left him needing '24-hour care'
RONNIE CORBETT sadly passed away aged 85 back in March 2016. Just after his death, Corbett's devoted wife revealed more about the entertainer's ill health and his amyotrophic lateral sclerosis diagnosis that came as a complete shock to them both. (Source: Daily Express - Health)
Source: Daily Express - Health - April 2, 2022 Category: Consumer Health News Source Type: news

FDA Advisory Panel Narrowly Votes Against New ALS Drug
THURSDAY, March 31, 2022 -- In a close vote, an advisory panel for the U.S. Food and Drug Administration decided not to recommend the approval of an experimental drug for amyotrophic lateral sclerosis (ALS). The panel ' s decision had been closely... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2022 Category: Pharmaceuticals Source Type: news

FDA Advisory Panel Rejects Novel ALS Drug FDA Advisory Panel Rejects Novel ALS Drug
A US Food and Drug Administration advisory committee is unconvinced by that a new drug for amyotrophic lateral sclerosis is effective.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 31, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

 New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds
With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients. (Source: NYT Health)
Source: NYT Health - March 30, 2022 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Drugs (Pharmaceuticals) Clinical Trials Amyotrophic Lateral Sclerosis Research Placebos your-feed-healthcare Source Type: news

FDA Reviewers Give Thumbs Down to New ALS Drug
TUESDAY, March 29, 2022 -- Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for amyotrophic lateral sclerosis (ALS). In an analysis of Amylyx... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2022 Category: Pharmaceuticals Source Type: news

Stakes Are High Ahead of FDA Panel Vote on ALS Drug
MONDAY, March 28, 2022 -- Advocacy groups are pressing U.S. federal regulators to fast-track approval of an experimental drug treatment for amyotrophic lateral sclerosis (ALS), with a decision expected this week. The push to approve the drug, so far... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2022 Category: Pharmaceuticals Source Type: news

Stakes Are High Ahead of FDA Panel Vote on ALS Drug
MONDAY, March 28, 2022 -- Advocacy groups are pressing U.S. federal regulators to fast-track approval of an experimental drug treatment for the deadly neurological disease ALS (amyotrophic lateral sclerosis), with a decision expected this week. The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2022 Category: General Medicine Source Type: news

Brain Implant Allows Fully Paralyzed Patient to Communicate Brain Implant Allows Fully Paralyzed Patient to Communicate
An experimental brain implant has allowed a man with amyotrophic lateral sclerosis who was unable to speak or move to communicate.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 24, 2022 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news